Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATE Antibe Therapeutics	C$0.30	C$0.52	C$0.15 ▼ C$1.23	C$15.54M	0.12	135,475 shs	N/A
GMTX Gemini Therapeutics	$27.00 +0.1%	$53.77	$1.16 ▼ $14.10	$1.17B	-0.12	189,291 shs	554,061 shs
RVX Resverlogix	C$0.06	C$0.06	C$0.05 ▼ C$0.16	C$16.33M	0.78	37,265 shs	36,650 shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATE Antibe Therapeutics	0.00%	0.00%	-30.59%	-67.93%	-45.37%
GMTX Gemini Therapeutics	-5.89%	-11.53%	-55.45%	-59.07%	-13.88%
RVX Resverlogix	+9.09%	+9.09%	0.00%	-7.69%	-62.50%

SHOCKING Crypto Leak… (Ad)

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATE Antibe Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATE Antibe Therapeutics	2.00	Hold	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest RVX, ATE, BVXP, GMTX, and TILS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/4/2024	ATE Antibe Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATE Antibe Therapeutics	C$9.71M	1.60	C$0.48 per share	0.61	C$0.49 per share	0.60
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
RVX Resverlogix	N/A	N/A	C$0.00 per share	132.50	C($0.26) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATE Antibe Therapeutics	-C$18.24M	-C$0.35	N/A	∞	N/A	N/A	-52.72%	-19.13%	7/4/2024 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
RVX Resverlogix	-C$12.82M	-C$0.05	N/A	∞	N/A	N/A	N/A	-37.10%	5/9/2024 (Estimated)

Latest RVX, ATE, BVXP, GMTX, and TILS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/14/2024	Q3 2024	ATE Antibe Therapeutics	-C$0.12	-C$0.08	+C$0.04	-C$0.08	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATE Antibe Therapeutics	C$0.05	16.95%	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATE Antibe Therapeutics	0.29	10.06	9.58
GMTX Gemini Therapeutics	N/A	71.49	71.49
RVX Resverlogix	N/A	0.11	0.04

Ownership

Institutional Ownership

Company	Institutional Ownership
ATE Antibe Therapeutics	N/A
GMTX Gemini Therapeutics	75.42%
RVX Resverlogix	N/A

Insider Ownership

Company	Insider Ownership
ATE Antibe Therapeutics	7.94%
GMTX Gemini Therapeutics	12.90%
RVX Resverlogix	43.19%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ATE Antibe Therapeutics	11	52.67 million	N/A	Not Optionable
GMTX Gemini Therapeutics	31	43.33 million	37.74 million	Not Optionable
RVX Resverlogix	19	272.17 million	N/A	Not Optionable

RVX, ATE, BVXP, GMTX, and TILS Headlines

Source	Headline
	Resverlogix Announces Change to Its Board of Directors finance.yahoo.com - February 21 at 8:02 PM
	Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits finance.yahoo.com - January 11 at 10:03 AM
	Closing Bell: Resverlogix Corp flat on Tuesday (RVX) theglobeandmail.com - January 4 at 6:16 PM
	Resverlogix Corp. (RVX) Earnings Dates & Reports investing.com - December 19 at 7:28 PM
	Resverlogix Corp RVXCF morningstar.com - November 18 at 5:49 PM
	Resverlogix Corp RVX morningstar.com - November 1 at 11:18 AM
	Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX) theglobeandmail.com - October 18 at 7:46 AM
	Resverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy finanznachrichten.de - October 4 at 10:11 AM
	Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy finance.yahoo.com - October 4 at 10:11 AM
	Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight finance.yahoo.com - September 26 at 8:50 PM
	Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes finance.yahoo.com - August 29 at 10:13 AM
	Closing Bell: Resverlogix Corp up on Wednesday (RVX) theglobeandmail.com - August 24 at 3:35 PM
	Closing Bell: Resverlogix Corp flat on Monday (RVX) theglobeandmail.com - August 14 at 10:02 PM
	Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A) theglobeandmail.com - July 12 at 7:21 AM
	Resverlogix Announces Warrant Repricing and One-Year Extension finance.yahoo.com - June 29 at 11:09 PM
	Resverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders finanznachrichten.de - June 20 at 7:31 PM
	Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders finance.yahoo.com - June 20 at 7:31 PM
	Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients finance.yahoo.com - June 12 at 6:42 PM
	Canadian Investment Regulatory Organization Trading Halt - RVX.WT.A finance.yahoo.com - June 7 at 1:32 PM
	Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A) theglobeandmail.com - June 6 at 10:49 AM
	Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A) theglobeandmail.com - May 25 at 12:52 AM
	CBOE RUSSELL 2000 VOLATILITY IN (^RVX) finance.yahoo.com - May 18 at 12:38 AM
	Bromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzz news.google.com - May 13 at 3:47 PM
	Resverlogix : MD&A Q1 2023 - Marketscreener.com news.google.com - May 12 at 3:50 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
Lockheed Martin Stock Aims for a Fresh All-Time High
April 23, 2024 9:59 AM
View Lockheed Martin Stock Aims for a Fresh All-Time High
3 Cheap Stocks That Shouldn’t Be Cheap for Long
March 26, 2024 9:49 AM
View 3 Cheap Stocks That Shouldn’t Be Cheap for Long
3 High Dividend Stocks to Replace Lower Savings Yields Ahead
April 9, 2024 9:15 AM
View 3 High Dividend Stocks to Replace Lower Savings Yields Ahead

All Headlines

Company Descriptions

Antibe Therapeutics

TSE:ATE

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Gemini Therapeutics

NASDAQ:GMTX

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Resverlogix

TSE:RVX

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial